Goals
- Increase the number and quality of early phase clinical trials
- Develop informative biomarkers (discovery, optimisation, validation, PK/PD, biological effective dose)
- Develop and validate generic indicators of tumour apoptosis and anti-angiogenesis
- Develop clinical proteomics/metabolomics
- Conduct early phase Clinical Immunology trials and translational PD
- Develop, integrate and expand imaging methodologies in preclinical models and early clinical trials
- Increase capability to deliver targeted radiotherapies
- Develop radiogenomics and image guided radiotherapy
- Integrate GCLP compliant Laboratory QA systems into early clinical trials
- Expertise in complex first into man Phase I trials
- Wide patient population
- Full imaging facilities
- Radiopharmaceutical development facilities and expertise
- Clinical Experimental Pharmacology Labs running PK and PD to GCLP
- Genomics
- Clinical proteomics
Increase text
Decrease text
Print this page